M&A Deal Summary |
|
|---|---|
| Date | 2017-02-27 |
| Target | Stevie K Cosmetics Pty |
| Sector | Consumer Products |
| Buyer(s) | InnovaDerma |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Consumer Products |
| Employees | 38 |
| Revenue | 10M GBP (2021) |
InnovaDerma specializes in research, manufacture and marketing of clinically proven products in life sciences, beauty and personal care products. InnovaDerma was founded in 2014 and is based in London, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Consumer Products M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 3 |
| Country: Australia M&A | 2 of 2 |
| Year: 2017 M&A | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-27 |
Charles & Lee Pty
Australia Charles + Lee is an affordable alternative premium range of men's skincare, marketed as an effective and understated brand, containing natural and organic ingredients. It is cruelty free and has been certified by the Roundtable on Sustainable Palm Oil Association. The products are Australian made, currently sold online at the brand's own website and online at Urban Outfitters in Australia, New Zealand, the US, and Canada |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-02 |
Ergon Medical
East Sussex, United Kingdom Ergon Medical Ltd. the owner of the intellectual property rights of ProlongTM, the world's only medical device cleared by the U.S. Food & Drug Administration ("FDA") for premature ejaculation. Prolong is a Class II vibrating medical device as classified by the FDA and used as part of a climax control programme for males who suffer from premature ejaculation. It is designed to increase the time between arousal and ejaculation through the use of the training sessions using the stimulating vibratory effects of the device on the penis as part of the "Start-Stop" technique. Prolong offers an affordable, pain-free, one-off, or long-term treatment option with no side effects. |
Buy | £1M |